2,400+ researchers supplied
99+ COAs published
6-panel tested every lot
Processing within 1–3 business days
FREE SHIPFree U.S. shipping on orders over $150Free U.S. shipping on orders over $150
Free U.S. shipping on orders over $150GHRP-6 is a ghrelin receptor agonist studied for its ability to stimulate endogenous growth hormone release and modulate appetite, energy balance, and neuroendocrine signaling.
Through activation of GHS-R1a and downstream pathways such as GH/IGF-1 and prolactin, GHRP-6 has been explored for effects on body composition, organ protection, immune regulation, and sleep physiology.
Growth Hormone–Releasing Peptide-6 (GHRP-6) is a synthetic hexapeptide that promotes growth hormone (GH) release by activating hypothalamic and pituitary signaling pathways.
What distinguishes GHRP-6 from other GHRPs is its orexigenic and neuroendocrine signaling [1]. GHRP-6 is a potent appetite-stimulating agent, reflecting strong activation of central ghrelin pathways involved in hunger perception and meal initiation.
This characteristic has made it a valuable research tool for studying the neural integration of appetite, growth hormone dynamics, and metabolic signaling.
At the receptor level, GHRP-6 activates GHS-R1a, triggering downstream GH/IGF-1 axis activity. Through this pathway, GHRP-6 indirectly influences:
In experimental settings, GHRP-6 increases secretion of other pituitary hormones, including prolactin and cortisol, highlighting its broader impact on neuroendocrine regulation [2, 3].
GHRP-6 can cause release of GH and downstream IGF-1 effects independent of GHRH or somatostatin. This occurs through activation of GHS-R1a [4].
GHRP-6 has unique effects on appetite regulation and body composition.
An animal study investigated the effects of GHRP-6 on food intake, body weight, and fat accumulation. Researchers compared adrenal-intact with adrenalectomised (ADX) rats (no glucocorticoid secretion) [5].
Rats received twice-daily subcutaneous injections of GHRP-6 (250 μg/kg) for two weeks. Results showed:
GHRP-6–induced body weight gain is not dependent on glucocorticoids, but activation of the HPA axis contributes to fat mass accumulation.
A study evaluated the effects of GHRP-6 on epithelial repair and organ protection in cell models of intestinal injury and rat models of multiple organ failure (MOF) induced by hepatic ischaemia–reperfusion [6].
In cells, GHRP-6 administration tripled cell migration compared with controls (p < 0.01). No increase in cell proliferation measured by [³H]-thymidine incorporation, indicating enhanced cellular motility rather than uncontrolled growth.
In the in vivo MOF model, ischaemia–reperfusion caused substantial tissue injury, including:
In the rat MOF model, results showed that:
GHRP-6 directly enhances epithelial repair through increased cell migration and provides broad organ-protective effects, supporting further investigation as a research strategy for mitigating inflammatory and ischemic organ injury.
GHRP-6 has been studied for its influence on sleep architecture.
A clinical study investigated how different routes of administration of GHRP-6 influence sleep architecture and endocrine hormone secretion in healthy young men [7].
Participants received either 300 μg/kg orally, 30 μg/kg intranasally, or 30 μg/kg sublingually at night.
Results showed that:
Results indicate that GHRP-6 can modulate both endocrine secretion and sleep, but that intranasal delivery was the most effective in influencing nocturnal GH secretion and sleep-related parameters.
References
1 Yahashi, S., Kang, K. S., Kaiya, H. and Matsuda, K. (2012) GHRP-6 mimics ghrelin-induced stimulation of food intake and suppression of locomotor activity in goldfish. Peptides, Elsevier BV 34, 324–328
2 Carmignac, D. F., Bennett, P. A. and Robinson, I. C. (1998) Effects of growth hormone secretagogues on prolactin release in anesthetized dwarf (dw/dw) rats. Endocrinology, The Endocrine Society 139, 3590–3596
3 Oliveira, J. H. A., Vieira, J. G. H., Abucham, J. and Lengyel, A. M. J. (2003) GHRP-6 is able to stimulate cortisol and ACTH release in patients with Cushing’s disease: comparison with DDAVP. J. Endocrinol. Invest., Springer Science and Business Media LLC 26, 230–235
4 Micic, D., Mallo, F., Peino, R., Cordido, F., Leal-Cerro, A., Garcia-Mayor, R. V., et al. (1993) Regulation of growth hormone secretion by the growth hormone releasing hexapeptide (GHRP-6). The Journal of pediatric endocrinology, J Pediatr Endocrinol 6 https://doi.org/10.1515/JPEM.1993.6.3-4.283
5 Tung, Y. L., Hewson, A. K. and Dickson, S. L. (2004) Glucocorticoid-dependent stimulation of adiposity and appetite by a ghrelin mimetic in the rat. Eur. J. Endocrinol., Oxford University Press (OUP) 150, 905–911
6 Cibrián, D., Ajamieh, H., Berlanga, J., León, O. S., Alba, J. S., Kim, M. J.-T., et al. (2006) Use of growth-hormone-releasing peptide-6 (GHRP-6) for the prevention of multiple organ failure. Clin. Sci. (Lond.), Portland Press Ltd. 110, 563–573
7 Frieboes, R. M., Murck, H., Antonijevic, I. A. and Steiger, A. (1999) Effects of growth hormone-releasing peptide-6 on the nocturnal secretion of GH, ACTH and cortisol and on the sleep EEG in man: role of routes of administration: Sleep endocrinology after GHRP-6. J. Neuroendocrinol., Wiley 11, 473–478
Research Use Only. All findings described above are derived from preclinical studies (animal models and in vitro experiments). GHRP-6 is not approved by the FDA for any diagnostic or therapeutic use in humans. Genesis Peptides makes no claims regarding human clinical efficacy. This product is sold exclusively for laboratory research.
Every lot undergoes six independent assays before release. Results are published in the lot-specific Certificate of Analysis.
Every lot undergoes our 6-panel testing protocol: identification by ESI-MS, purification by RP-HPLC, conformity, sterility screening, quantification of net peptide content, and LAL endotoxin screening. Full analytical data is published in the Certificate of Analysis for each lot.
Lyophilized peptides should be stored at -20°C or below for long-term stability. Once reconstituted, peptides should be stored at 2–8°C and used within a reasonable timeframe depending on the specific compound. Avoid repeated freeze-thaw cycles. Always store in a dry environment away from direct light.
Orders are processed within 1–3 business days after payment confirmation. Orders placed after 3:00 PM Pacific time or on weekends and holidays will begin processing the next business day. We offer free standard shipping on orders over $150. All orders are shipped in insulated packaging with ice packs when necessary. Standard delivery typically takes 2–4 business days within the continental US.
No. All compounds sold by Genesis Peptides are strictly for in vitro and preclinical laboratory research purposes only. They are not approved for human consumption, therapeutic use, or diagnostic purposes. By purchasing, you confirm the products will be used solely for legitimate research applications.
A Certificate of Analysis (COA) is a document issued by our analytical laboratory that reports the results of all quality control tests performed on a specific lot of product. Each COA includes HPLC chromatograms, mass spectra, endotoxin results, and quantification data where applicable. COAs are available in our COA Library for every lot we have shipped.
Yes. We offer volume pricing for universities, research institutions, and laboratories with recurring needs. Discounts begin at 100+ units and scale with volume. Contact our team for a custom quote tailored to your research requirements.
FOR RESEARCH USE ONLY — Products are sold exclusively for in vitro and preclinical laboratory research. Not for human consumption or administration. Not intended for diagnostic or therapeutic use. These statements have not been evaluated by the FDA.
Summary GHRP-6 stimulates growth hormone release, with cardioprotective and myoprotective benefits. Human Growth Hormone (HGH) Frag 176–191 is a synthetic 16-amino acid fragment of GH that isolates and enhances lipolysis without the growth-promoting and effects of full-length hGH. Together, GHRP-6 increases endogenous GH while HGH Frag 176–191 amplifies peripheral lipolysis, creating complementary effects. What Is GHRP-6? GHRP-6 (Growth Hormone–Releasing Peptide-6) is a synthetic hexapeptide and member of the growth hormone secretagogue family [1]. It primarily functions as a ghrelin analog, binding to and activating the ghrelin receptor GHS-R1a and CD36 receptors. GHS-R1a is expressed in the hypothalamus, pituitary, hippocampus, along with the pancreas and liver. The CD36 is expressed in the cardiovascular system and macrophages, which may contribute to GHRP-6’s cardioprotective and anti-fibrotic effects observed in experimental models [1,2]. Originally developed as a growth hormone secretagogue, GHRP-6’s pharmacologic profile has expanded to include anabolic, cytoprotective, and potential cardiometabolic applications in preclinical research. GHRP-6 works by stimulating the growth hormone/IGF-1 axis, increasing pituitary growth hormone release, and promoting downstream IGF-1 production and anabolic effects [1]. Since it’s the only GHRP that increases hunger and appetite, it may be helpful in conditions where increased caloric intake is beneficial [3]. Through interacting with CD36, which plays roles in fatty acid metabolism, inflammation, and tissue damage, GHRP-6 is thought to confer tissue-protective effects [1]. Importantly, GHRP-6 appears to act through mechanisms distinct from those of growth hormone–releasing factors [2]. What Is HGH Frag 176–191? Human Growth Hormone (HGH) Frag 176–191 is a modified peptide fragment derived from the C-terminal region of human growth hormone [4]. This 16-amino acid fragment corresponds to amino acids 176–191 of the full HGH molecule, modified with a tyrosine-to-phenylalanine substitution at position 191 to enhance stability and activity [4]. Unlike full-length growth hormone, HGH frag 176–191 does not replicate the complete growth-promoting effects of hGH [4]. Instead, it appears to isolate and amplify one specific functional region of the hormone, exerting more selective metabolic effects, including enhanced lipolysis, increased lipid utilization, and adipose tissue metabolism without strongly stimulating IGF-1-mediated growth pathways [4]. HGH Frag 176–191 and GHRP-6 Synergy GHRP-6 and HGH frag 176–191 act at distinct points within the growth hormone signaling network. GHRP-6 works upstream through the ghrelin receptor, leading to downstream effects on metabolism, tissue repair, and lipolysis via physiologic GH pulses [5]. In contrast, HGH frag 176–191 exerts downstream effects, representing a small portion of the growth hormone molecule associated with fat metabolism [6]. HGH frag 176–191 appears to act more selectively on adipose tissue, with minimal activation of broader growth or IGF-1 pathways [6]. Mechanistically, this difference suggests the potential for complementary effects. By increasing natural pulsatile growth hormone release, GHRP-6 may enhance the body’s natural growth hormone rhythm, influencing substrate partitioning, promoting lipolysis, and supporting lean tissue maintenance [7]. Endogenous growth hormone’s metabolic actions include stimulating growth hormone–sensitive lipase, increasing fat breakdown, and reducing glucose uptake into adipocytes, shifting the body towards greater fat utilization. However, these effects depend heavily on overall energy balance and insulin status [3]. HGH frag 176–191 has demonstrated increased fat oxidation and reduced adipose accumulation in rodent models, without significantly stimulating IGF-1 or generalized tissue growth [6]. Because the fragment appears to emphasize fat-specific metabolic signaling, while GHRP-6 enhances upstream GH availability, their combined use has been hypothesized to align systemic hormone signaling with more targeted adipose effects. Doses and Ratios The combined effect of GHRP-6 and HGH fragment 176–191 could create a stronger shift towards fat utilization while maintaining, or even concurrently building lean mass. Additionally, they engage different receptor pathways and are unlikely to compete directly, which makes complementary signaling biologically plausible [6, 7]. However, this is largely based on mechanistic reasoning rather than direct clinical studies examining the two together, and conclusions about combined effects are unknown. The 1:1 ratio of 5 mg of HGH frag 176–191 and 5 mg of GHRP-6 aligns with dosages studied in human metabolic trials evaluating fat metabolism. References: 1 Berlanga-Acosta, J., Cibrian, D., Valiente-Mustelier, J., Suárez-Alba, J., García-Ojalvo, A., Falcón-Cama, V., et al. (2024) Growth hormone releasing peptide-6 (GHRP-6) prevents doxorubicin-induced myocardial and extra-myocardial damages by activating prosurvival mechanisms. Front. Pharmacol., Frontiers Media SA 15, 1402138 2 Wu, D., Chen, C., Zhang, J., Bowers, C. Y. and Clarke, I. J. (1996) The effects of GH-releasing peptide-6 (GHRP-6) and GHRP-2 on intracellular adenosine 3’,5'-monophosphate (cAMP) levels and GH secretion in ovine and rat somatotrophs. J. Endocrinol., Bioscientifica 148, 197–205 3 Granado, M., García-Cáceres, C., Frago, L. M., Argente, J. and Chowen, J. A. (2010) The positive effects of growth hormone-releasing peptide-6 on weight gain and fat mass accrual depend on the insulin/glucose status. Endocrinology, The Endocrine Society 151, 2008–2018 4 Habibullah, M. M., Mohan, S., Syed, N. K., Makeen, H. A., Jamal, Q. M. S., Alothaid, H., et al. (2022) Human growth hormone fragment 176-191 peptide enhances the toxicity of doxorubicin-loaded Chitosan nanoparticles against MCF-7 breast cancer cells. Drug Des. Devel. Ther., Informa UK Limited 16, 1963–1974 5 Fairhall, K. M., Mynett, A. and Robinson, I. C. (1995) Central effects of growth hormone-releasing hexapeptide (GHRP-6) on growth hormone release are inhibited by central somatostatin action. J. Endocrinol., Bioscientifica 144, 555–560 6 Heffernan, M. A., Thorburn, A. W., Fam, B., Summers, R., Conway-Campbell, B., Waters, M. J., et al. (2001) Increase of fat oxidation and weight loss in obese mice caused by chronic treatment with human growth hormone or a modified C-terminal fragment. Int. J. Obes. Relat. Metab. Disord., Springer Science and Business Media LLC 25, 1442–1449 7 Lei, T., Buchfelder, M., Fahlbusch, R. and Adams, E. F. (1995) Growth hormone releasing peptide (GHRP-6) stimulates phosphatidylinositol (PI) turnover in human pituitary somatotroph cells. J. Mol. Endocrinol., Bioscientifica 14, 135–138
Snapshot: Gonadorelin is a synthetic version of gonadotropin-releasing hormone (GnRH), a key signalling molecule produced in the hypothalamus [1]. It triggers the pituitary to release luteinizing hormone (LH) and follicle-stimulating hormone (FSH) [2]. Clinically, it is used to assess hypothalamic-pituitary function and to induce ovulation in select cases [2]. What Is Gonadorelin Peptide? Gonadorelin peptide is a low-weight, synthetic analogue structurally identical to the body’s endogenous GnRH released by the hypothalamus [1]. It acts as a central regulator of the hypothalamic-pituitary-gonadal axis, stimulating pituitary release of LH and FSH to control reproduction, sex hormone production, and fertility [1]. It binds to LHRH receptors on pituitary gonadotroph cells to stimulate the release of LH and FSH; with continuous exposure, these receptors become desensitized [3]. Clinically, it is used to assess hypothalamic–pituitary function and in select cases of hypothalamic amenorrhea [3]. It is listed as a prohibited substance by the World Anti-Doping Agency (WADA) and can be detected in urine [4]. Gonadorelin peptide effects and uses Gonadorelin has broad clinical applications across reproductive medicine, endocrinology, and gynecology [5]. By providing direct stimulation to the hypothalamic-pituitary-gonadal axis, it has shown benefits for restoring physiological hormone signalling and modulating it for diagnostic or therapeutic purposes [5]. Gonadorelin has been clinically explored to induce ovulation and support fertility interventions, assess endocrine function, manage hormone-sensitive conditions, and treat gynecologic disorders, including endometriosis and uterine fibroids [5]. It has also been studied for contraceptive use and for protecting ovarian function during chemotherapy [6]. Ovulation induction Evidence suggests gonadorelin can support ovulation through restoration or modulation of the normal hypothalamic-pituitary axis signalling [7]. By mimicking endogenous GnRH, gonadorelin can normalize LH and FSH release, re-establish physiologic GnRH pulsatility, and promote ovulatory function in hyperandrogenic disorders and gonadotropin imbalance [1]. Experimental models demonstrate meaningful ovulation rates with gonadorelin compared to controls, supporting its role as an effective ovulation-induction agent [8]. It works via triggering a pituitary LH surge that promotes dominant follicle ovulation and corpus luteum formation [8]. In one animal model, gonadorelin increased sex steroid levels and induced ovulation in 67% of treated females, while no control subjects ovulated [9]. Hormonal Disorder Treatments Gonadorelin modulates the hypothalamic-pituitary-gonadal axis to regulate sex hormone signalling across a range of conditions [10]. When administered repeatedly, it can induce a reversible pituitary desensitization, causing temporary suppression of gonadotropin signalling to sex organs [10]. Clinically, gonadorelin has shown benefits in: Hormone-sensitive prostate cancer [11]. Premenopausal hormone-sensitive breast cancer, where suppression of ovarian steroid production is therapeutically beneficial [12]. Hormonal dysregulation where an induced controlled, reversible hypogonadotropism in conditions of hormone dysregulation can allow endocrine signalling to stabilize [13]. For example, it can help manage precocious puberty to suppress premature activation of the reproductive axis [14]. Managing endometriosis and uterine fibroid size, where the peptide can produce temporary remission of the diseases [14]. Severe, recurrent acute porphyria where prophylactic use of gonadorelin analogues reduced attack frequency in approximately half of treatment courses [15]. Animal studies also show benefits. A large field trial involving dairy cows with cystic ovarian disease reported resolution rates exceeding 90% after a single treatment, regardless of timing postpartum, highlighting the reliability of its hormonal action [16]. Boosting Success Rates of Fertility Treatments Gonadorelin is thought to improve fertility treatment outcomes by stabilizing pituitary signalling during controlled ovarian stimulation [17]. By suppressing erratic or premature LH release, gonadorelin helps to prevent premature ovulation and hormone fluctuations that can disrupt cycle timing [17]. This control can increase the proportion of adequate stimulation cycles, reduce cycle cancellation, and may allow greater flexibility in scheduling stimulation and optimizing IVF protocols. Animal models have found that adding gonadorelin can support pregnancy outcomes. A large cattle study in Brazil found that administering gonadorelin at the time of fixed-time embryo transfer significantly improved conception rates at both 30 and 60 days of gestation compared with untreated controls [17]. Treated animals also showed reduced pregnancy loss, indicating that GnRH analogue use can enhance embryo transfer success, even under less favorable conditions [17]. Gonadorelin side effects There are several known side effects of gonadorelin peptide, with many largely related to predictable, reversible hypoestrogenic states. The most common are mild, including abdominal discomfort, short-lasting flushing, headaches, light-headedness, and nausea [18]. Following repeated doses, there have been reports in the literature of difficulty breathing, continuous flushing, and rapid heart rate, although they are rare [18]. Injection site reactions can occur, as well as hormonal side effects from estrogen depletion, including hot flashes, vaginal dryness, and reversible trabecular bone resorption [18, 2]. References 1 Torrini, F., Scarano, S., Palladino, P. and Minunni, M. (2023) Advances and perspectives in the analytical technology for small peptide hormones analysis: A glimpse to gonadorelin. J. Pharm. Biomed. Anal., Elsevier BV 228, 115312 2 Chrisp, P. and Goa, K. L. (1990) Nafarelin: A review of its pharmacodynamic and pharmacokinetic properties, and clinical potential in sex hormone-related conditions. Drugs, Springer Nature 39, 523–551 3 National Cancer Institute. (2020, February 7) Recombinant Gonadorelin. Definitions, Qeios https://doi.org/10.32388/9g8tac 4 The Prohibited List. World Anti Doping Agency https://www.wada-ama.org/en/prohibited-list 5 Conn, P. M. and Crowley, W. F., Jr. (1994) Gonadotropin-releasing hormone and its analogs. Annu. Rev. Med., Annual Reviews 45, 391–405 6 Lambertini, M., Moore, H. C. F., Leonard, R. C. F., Loibl, S., Munster, P., Bruzzone, M., et al. (2018) Gonadotropin-releasing hormone agonists during chemotherapy for preservation of ovarian function and fertility in premenopausal patients with early breast cancer: A systematic review and meta-analysis of individual patient-level data. J. Clin. Oncol., J Clin Oncol 36, 1981–1990 7 Picard-Hagen, N., Lhermie, G., Florentin, S., Merle, D., Frein, P. and Gayrard, V. (2015) Effect of gonadorelin, lecirelin, and buserelin on LH surge, ovulation, and progesterone in cattle. Theriogenology, Elsevier BV 84, 177–183 8 Lima, F. S., Ayres, H., Favoreto, M. G., Bisinotto, R. S., Greco, L. F., Ribeiro, E. S., et al. (2011) Effects of gonadotropin-releasing hormone at initiation of the 5-d timed artificial insemination (AI) program and timing of induction of ovulation relative to AI on ovarian dynamics and fertility of dairy heifers. J. Dairy Sci., American Dairy Science Association 94, 4997–5004 9 Oliveira, R. G. de S., de Morais, I. S., Paixão, R. V., Bandeira, I. C., Duncan, W. L. P. and O’Sullivan, F. L. de A. (2025) Effects of gonadorelin on gonadotropin expression, plasma sex steroid concentrations and ovarian follicle dynamics in mature tambaqui (Colossoma macropomum). Comp. Biochem. Physiol. B Biochem. Mol. Biol., Elsevier BV 279, 111126 10 Wang, X., Zhang, Z. X., Chen, J., Fu, D., Du, M., Chen, Y., et al. (2025) Efficacy and safety of pulsatile GnRH pump therapy in male infants with congenital hypogonadotropic hypogonadism. Endocr. Connect., Bioscientifica Ltd 14 https://doi.org/10.1530/EC-24-0655 11 Barrett, R., Barrett, R., Dhar, K. and Birch, B. (2021) Gonadorelins adherence in prostate cancer: A time-series analysis of England’s national prescriptions during the COVID-19 pandemic (from Jan 2019 to Oct 2020). BJUI Compass, Wiley 2, 419–427 12 Huerta-Reyes, M., Maya-Núñez, G., Pérez-Solis, M. A., López-Muñoz, E., Guillén, N., Olivo-Marin, J.-C., et al. (2019) Treatment of breast cancer with gonadotropin-releasing hormone analogs. Front. Oncol., Frontiers Media SA 9, 943 13 Shao W.-M., Bai W.-J., Chen Y.-M., Liu L. and Wang Y.-J. (2014) Micropump infusion of gonadorelin in the treatment of hypogonadotropic hypogonadism in patients with pituitary stalk interruption syndrome: cases analysis and literature review. Beijing Da Xue Xue Bao, Beijing Da Xue Xue Bao Yi Xue Ban 46, 642–645 14 Foye, W. O. (2008) Foye’s principles of medicinal chemistry, Lippincott williams & wilkins 15 Schulenburg-Brand, D., Gardiner, T., Guppy, S., Rees, D. C., Stein, P., Barth, J., et al. (2017) An audit of the use of gonadorelin analogues to prevent recurrent acute symptoms in patients with acute porphyria in the United Kingdom. JIMD Rep., Springer Berlin Heidelberg 36, 99–107 16 Hooijer, G. A., Frankena, K., Valks, M. M. and Schuring, M. (1999) Treatment of cystic ovarian disease in dairy cows with gonadotrophin-releasing hormone: a field study. Vet. Q., Informa UK Limited 21, 33–37 17 Defensor, M. L., Faria, A. C. F., Marques, F. L. A., Cadima, G. P., Mafra, M. O. and Santos, R. M. dos. (2021, September 13) Effect of treatment with gonadoreline at the embryo transfer on pregnancy outcomes in bovine. Research Square https://doi.org/10.21203/rs.3.rs-765941/v1 18 (2024, February 15) Gonadorelin: Indications, Side Effects, Warnings. Drugs.com https://www.drugs.com/cdi/gonadorelin.html
Snapshot: Hexarelin is a synthetic hexapeptide and potent growth hormone secretagogue that selectively activates GHS-R (ghrelin) receptors to simulate endogenous, pulsatile GH release. Preclinical studies suggest potential roles in cardiomyocyte protection under ischemic stress, metabolic and lipid-regulating pathways, skeletal muscle mass preservation, and organ-protective stress-response signalling. What Is Hexarelin? Hexarelin (examorelin) is a synthetic hexapeptide (His-D-2-Methyl-Trp-Ala-Trp-D-Phe-Lys-NH2) belonging to the group of growth hormone secretagogues (GHS) [1]. It was developed as a selective GHS-R ghrelin receptor agonist to enhance the body’s natural growth-hormone output, rather than replace it with exogenous hormone [1]. Through high-affinity receptor binding in the hypothalamus and pituitary, hexarelin activates G-protein coupled signalling, intracellular calcium mobilization, and cAMP-linked pathways that support pulsatile GH release patterns [2]. The peptide incorporates non-natural amino acids including D-2-methyltryptophan, D-phenylalanine, and lysine amide, increasing resistance to enzymatic degradation and improving its pharmacokinetic stability [3]. It is metabolized in the liver with renal elimination and remains analytically detectable for up to 8 hours post-administration [3]. Hexarelin Peptide Benefits In addition to GH signalling, hexarelin is widely used in experimental and preclinical research to study cardiometabolic stress responses, intracellular calcium regulation, oxidative stress and inflammatory markers, and survival-associated pathways in cardiac and skeletal muscle models. Cardiovascular Protection Hexarelin activates two key receptors found directly in cardiac muscle and blood vessels, GHSR-1a receptor and CD36 [4]. Because these receptors are present in heart muscle cells themselves, many of hexarelin’s effects appear to come from local, tissue-level signalling inside the heart, rather than through increasing circulating growth hormone [4]. In many experimental models, hexarelin enhanced myocardial contractility. Hexarelin has been shown to improve intracellular calcium handling and activates downstream kinase pathway (including protein kinase C signalling), resulting in a positive inotropic effect without increasing heart rate or imposing excess hemodynamic load [4]. Hexarelin has also demonstrated cytoprotective effects under stress conditions, including heart failure, ischemia, and toxin exposure [4]. It attenuates cardiomyocyte and endothelial apoptosis, reduces DNA fragmentation, and promotes survival-associated signalling, thereby supporting the preservation of myocardial tissue over time [4]. In ischemic-reperfusion models, hexarelin reduced infarct size and improved recovery of post-ischemic ventricular performance, and heart conduction stabilization [4]. Chronic cardiovascular stress is a driver of fibrotic remodelling, and hexarelin seems to mitigate this process by downregulating collagen I and III expression, reducing profibrotic signaling, and enhancing metalloprotease activity – changes consistent with reduced myocardial stiffness and improved diastolic function [4]. Combined, these findings suggest hexarelin may help the heart contract more efficiently, withstand stress, and recover more efficiently following injury, with actions driven largely by its direct interaction with cardiac receptors [4]. Body Composition & Metabolic Health Hexarelin and related growth-hormone secretagogues have been investigated for their effects on lipid metabolism, insulin-resistance markers, skeletal muscle mass preservation, and cachexia-induced signalling pathways. In a study of healthy older adults, those with higher total fat mass, body fat percentage, BMI or bodyweight showed a smaller growth hormone response after a single dose of hexarelin [5]. Fat mass was the strongest predictor of response, while gender’s predictive effect was not significant once body composition was adjusted [5]. This trend occurred across a continuum, with even moderate increases in body fat linked to reduced GH response. This suggests higher adiposity can blunt GH-sectretagogue signalling [5]. Beyond hormone responsiveness, preclinical research indicates hexarelin may support metabolic resilience and cellular protection [6]. In models of chemically induced pancreatic beta-cell damage, hexarelin reduced mitochondrial injury, oxidative stress, and activation of cell-death pathways, while preserving beta-cell structure and insulin levels [6]. These findings suggest a potential role in protecting beta-cell mass under oxidative and metabolic stress conditions [6]. Additional animal models have shown improvements in glucose and insulin tolerance, lowered liver and plasma triglycerides, and enhanced fat-cell differentiation and lipid handling [7]. These improvements occurred without increases in total body weight and were accompanied by a shift toward lower fat mass and higher lean mass, despite increased food intake [7]. These effects may relate, in part, to CD36-linked lipid metabolism pathways [7]. Organ Protection Research across cardiac, metabolic, and skeletal muscle systems indicates that hexarelin may exert organ-protective effects. It is thought these effects occur through activation of survival- and stress-response pathways, modulation of fibrosis and remodelling signals, stabilization of intracellular calcium dynamics, and protection of mitochondrial function under metabolic or toxic stress [8, 9, 10, 6]. These effects are currently described within experimental frameworks and mechanistic investigations, rather than clinical outcome studies. 1 Carpino, P. A. (2002) Recent developments in ghrelin receptor (GHS-R1a) agonists and antagonists. Expert Opin. Ther. Pat., Informa Healthcare 12, 1599–1618 2 Imbimbo, B. P., Mant, T., Edwards, M., Amin, D., Dalton, N., Boutignon, F., et al. (1994) Growth hormone-releasing activity of hexarelin in humans. A dose-response study. Eur. J. Clin. Pharmacol., Springer 46, 421–425 3 Ghigo, E., Arvat, E., Gianotti, L., Imbimbo, B. P., Lenaerts, V., Deghenghi, R., et al. (1994) Growth hormone-releasing activity of hexarelin, a new synthetic hexapeptide, after intravenous, subcutaneous, intranasal, and oral administration in man. J. Clin. Endocrinol. Metab., The Endocrine Society 78, 693–698 4 Mao, Y., Tokudome, T. and Kishimoto, I. (2014) The cardiovascular action of hexarelin. J. Geriatr. Cardiol. 11, 253–258 5 Rahim, A., O’Neill, P. and Shalet, S. M. (1998) The effect of body composition on hexarelin-induced growth hormone release in normal elderly subjects. Clin. Endocrinol. (Oxf.), Wiley 49, 659–664 6 Zhao, Y., Zhang, X., Chen, J., Lin, C., Shao, R., Yan, C., et al. (2016) Hexarelin protects rodent pancreatic Β-cells function from cytotoxic effects of streptozotocin involving mitochondrial signalling pathways in vivo and in vitro. PLoS One, Public Library of Science (PLoS) 11, e0149730 7 Mosa, R., Huang, L., Wu, Y., Fung, C., Mallawakankanamalage, O., LeRoith, D., et al. (2017) Hexarelin, a growth hormone secretagogue, improves lipid metabolic aberrations in nonobese insulin-resistant male MKR mice. Endocrinology, Endocrinology 158, 3174–3187 8 Guan, C., Li, C., Shen, X., Yang, C., Liu, Z., Zhang, N., et al. (2023) Hexarelin alleviates apoptosis on ischemic acute kidney injury via MDM2/p53 pathway. Eur. J. Med. Res., Springer Science and Business Media LLC 28, 344 9 Rossoni, G., De Gennaro Colonna, V., Bernareggi, M., Polvani, G. L., Müller, E. E. and Berti, F. (1998) Protectant activity of hexarelin or growth hormone against postischemic ventricular dysfunction in hearts from aged rats. J. Cardiovasc. Pharmacol., Ovid Technologies (Wolters Kluwer Health) 32, 260–265 10 Zambelli, V., Rizzi, L., Delvecchio, P., Bresciani, E., Rezoagli, E., Molteni, L., et al. (2021) Hexarelin modulates lung mechanics, inflammation, and fibrosis in acute lung injury. Drug Target Insights, Aboutscience Srl 15, 26–33